Full-Time

Market Access Manager

Private Insurance

Updated on 9/13/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

CA$112.3k - CA$152k/yr

Québec City, QC, Canada

In Person

Field-based across Quebec.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Financial analysis
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A bachelor's degree in life sciences, business, health economics, or a related field.
  • At least five years of relevant experience in market access, reimbursement, private insurance, payer strategy, or account management within the biopharmaceutical, private insurance, pharmacy benefit manager, benefits consulting, or payer sectors.
  • Professional fluency in French and English, with the ability to communicate effectively in English with colleagues and stakeholders outside Quebec.
Responsibilities
  • Develop and execute tailored private payer strategies for Quebec and assigned national private insurer accounts across the Amgen portfolio, including innovator and biosimilar products.
  • Develop and execute payer-specific reimbursement strategies to optimize patient access, coverage, and financial performance.
  • Deliver assigned market-access objectives, including product listing, reimbursement, patient access, and sustainable portfolio growth.
  • Identify market opportunities and access barriers using customer insights, claims data, and market intelligence.
  • Support launch readiness and lifecycle planning for pipeline and in-market products across assigned payer accounts.
  • Evolve payer strategies across the product lifecycle in response to market dynamics, competitive pressures, and policy changes.
  • Build and maintain strategic relationships with private insurers, pharmacy benefit managers, benefit consultants, and reimbursement decision-makers.
  • Lead complex payer negotiations and represent Amgen in appropriate external forums.
  • Identify mutually beneficial solutions that address payer priorities while supporting timely and sustainable patient access.
  • Partner with Pricing, Health Economics, Medical, Legal, Government Relations, Commercial, Regulatory, Finance, and Patient Support teams to develop and execute integrated private-insurance strategies.
  • Lead cross-functional planning for payer submissions, negotiations, reimbursement implementation, and lifecycle management.
  • Serve as the subject matter expert on Quebec private-insurance dynamics and assigned national payer accounts.
  • Contribute payer insights to brand and portfolio strategy and optimize the end-to-end patient access experience.
  • Communicate strategic insights, risks, and recommendations to senior leadership and cross-functional teams.
  • Support payer pricing and reimbursement strategies while balancing commercial objectives.
  • Assess trade-offs among access, pricing, and profitability and support payer-specific business cases.
  • Translate clinical, economic, and real-world evidence into payer value propositions.
  • Provide strategic input into payer evidence packages, budget-impact materials, and reimbursement submissions.
  • Monitor reimbursement performance, payer policy changes, and market developments, and recommend strategies to optimize long-term access.
  • Lead negotiation and lifecycle management of private payer agreements and product listing agreements.
  • Develop contracting and reimbursement solutions with cross-functional partners.
  • Ensure agreements and external engagements comply with legal, regulatory, privacy, compliance, pricing, finance, and corporate-governance requirements.
  • Monitor contractual performance and track performance against contractual terms and relevant access or financial KPIs.
  • Monitor private insurer policies, formulary trends, competitor activity, benefit-design changes, and broader market dynamics.
  • Generate actionable insights for portfolio planning, launches, negotiations, and lifecycle management.
  • Gather and synthesize payer-interaction insights to inform the Private Insurance Strategic Plan and support Commercial and cross-functional teams.
  • Identify emerging access risks and opportunities in the Quebec private-insurance market and assigned national accounts.
  • Maintain appropriate documentation, transparency, and governance throughout payer engagement and contracting activities.
Desired Qualifications
  • Experience working for a private insurer, pharmacy benefit manager, benefit consultant, or payer organization.
  • Demonstrated experience within a pharmaceutical or biopharmaceutical manufacturer focused on market access, reimbursement, private payer strategy, or account management.
  • Expertise in the Canadian private-payer landscape and Quebec-specific market dynamics.
  • Strong, established relationships across the private-insurance ecosystem, including insurers, pharmacy benefit managers, consultants, and healthcare stakeholders.
  • Deep understanding of drug-reimbursement processes, pricing frameworks, formulary decision-making, and private-payer coverage models.
  • Proven experience leading payer negotiations and managing complex agreements.
  • Ability to operate strategically and influence internal and external stakeholders.
  • Ability to analyze complex data and translate insights into actionable access strategies.
  • Communication, negotiation, relationship-management, and presentation skills.
  • Ability to work effectively in a matrixed organization.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.